freeze-thaw cycle comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-28. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
=== 1995 analysis === Samples of the St. Augustine carcass were again examined in 1995. They were subjected to electron microscopy and biochemical analysis in what was the most thorough examination of the preserved material to date. The results of the analyses, published in the Biological Bulletin, disputed the earlier findings of Gennaro and Mackal. These are shown in the following table:
Mural Painting: cool, dry, glue, tempera, sgraffito Easel Painting and Altars: canvas, board, altarpiece Sculptural and Ornamental Materials: stone, mortar, stucco, bronze, terracotta, wood Golden, polychrome, furniture and expertizing Archaeological and ethnographic materials: flooring, tiles, ceramic tiles, glass, archaeological remains, tapestry, vestment, robes Graphic and Documentary: drawing, scroll, prints, book, photograph, manuscript The intervention Area of Architectural Heritage comprises:
The use of mist-netting and photography, blood sampling (for DNA, immunological and other studies), the development of optics and the use of other new techniques for studying birds have reduced the need to collect specimens for research, yet collections continue to act as a vital shared resource for science (particularly taxonomy) and conservation. In an era of mass extinction, bird collections will evidence lost species.
== Pharmacology == Itopride acts as a selective dual D2 receptor antagonist and acetylcholinesterase inhibitor. There is evidence that itopride may have prokinetic effects throughout the gastrointestinal tract from the stomach to the end of the colon. The pharmacokinetics of itopride appear to differ between Asian and Caucasian populations, with Caucasians having 30-50 percent lower blood levels of itopride after oral administration. Itopride poorly penetrates across the blood brain barrier because of its high polarity and thus itopride does not tend to cause any central nervous system adverse effects. Itopride has no effect on potassium channels. Similarly to other D2 receptor antagonists, itopride has been found to dose-dependently increase prolactin levels.
Ian McCartney, Labour Party chairman at the time, said Galloway was the only Labour MP who "incited foreign forces to rise up against British troops". Tony Benn questioned why Galloway strove to remain in the Labour Party despite calling its leadership a "blood-splattered, lying, crooked group of war criminals". Benn added, "It put me off George Galloway in a fairly fundamental way". Following the 7 July 2005 London bombings, which killed 52 civilians, Galloway linked the attack to Western policies in the Middle East. He said Tony Blair and George W. Bush had "far more blood on their hands" than the terrorists who carried out the bombings, and called President Bush the world's "biggest terrorist".
Sources: en.wikipedia.org
== Early life == Nayib Armando Bukele Ortez was born on 24 July 1981 in San Salvador, El Salvador. His father was Armando Bukele Kattán, a businessman and industrial chemist, and his mother is Olga Marina Ortez. Bukele's father died in 2015. Bukele was the couple's first child. He has three younger brothers, Karim, Yusef, and Ibrajim, and has four paternal half-sisters and two paternal half-brothers. Bukele's father converted from Christianity to Islam in the 1980s, became an imam, and founded four mosques in El Salvador. Bukele's mother is Catholic. Bukele's paternal grandparents were Palestinian Christians who emigrated to El Salvador from Jerusalem and Bethlehem in 1921. His maternal grandfather was Greek Orthodox, and his maternal grandmother was Catholic. Bukele completed his secondary education at the Escuela Panamericana in 1999 at age 18. Bukele enrolled at Central American University in San Salvador to study legal sciences, aspiring to become a lawyer, but dropped out to work for the Nölck advertising agency, one of his father's businesses. Nölck campaigned for the Farabundo Martí National Liberation Front (FMLN), a left-wing Salvadoran political party. In 1999, Bukele founded the marketing company Obermet, also known as 4am Saatchi & Saatchi El Salvador, and was its president from 1999 to 2006 and from 2010 to 2012. The company ran political advertising for the FMLN presidential campaigns of Schafik Hándal in 2004 and Mauricio Funes in 2009.
February 14 – A second shutdown affecting only the Department of Homeland Security begins. February 16 – A mass shooting occurs at the Dennis M. Lynch Arena in Pawtucket, Rhode Island, during a high school ice hockey game. The attack results in the deaths of three people, and three others hospitalized. February 17 Tributes are paid to Jesse Jackson following the announcement of the civil rights leader's death at the age of 84. Tricia McLaughlin resigns as Assistant Secretary for Public Affairs in the United States Department of Homeland Security and will leave the Trump administration amidst backlash about Trump's hardline immigration policies. An avalanche kills eight skiers northwest of Lake Tahoe in California. San Antonio Express-News publishes a story about Tony Gonzales's affair. February 19 – Trump announces he is transferring $10 billion from the US government to his "Board of Peace" which he chairs. February 20 – Legal affairs of the second Trump presidency: The U.S. Supreme Court holds in a 6–3 ruling that the IEEPA does not give the President the power to set tariffs, striking down Trump's sweeping emergency tariffs via executive orders. February 21 – Trump announces that he will increase global tariffs to 15% following the Supreme Court decision the previous day, effective from February 24. February 22 – A 21-year-old man is shot and killed after entering the secure perimeter of Trump's Mar-a-Lago residence. The suspect is described as a white male carrying a shotgun and fuel can.
=== Perey's analysis === Eka-caesium was discovered on January 7, 1939, by Marguerite Perey of the Curie Institute in Paris, when she purified a sample of actinium-227 which had been reported to have a decay energy of 220 keV. Perey noticed decay particles with an energy level below 80 keV. Perey thought this decay activity might have been caused by a previously unidentified decay product, one which was separated during purification, but emerged again out of the pure actinium-227. Various tests eliminated the possibility of the unknown element being thorium, radium, lead, bismuth, or thallium. The new product exhibited chemical properties of an alkali metal (such as coprecipitating with caesium salts), which led Perey to believe that it was element 87, produced by the alpha decay of actinium-227. Perey then attempted to determine the proportion of beta decay to alpha decay in actinium-227. Her first test put the alpha branching at 0.6%, a figure which she later revised to 1%. Perey named the new isotope actinium-K (it is now referred to as francium-223) and in 1946, she proposed the name catium (Cm) for her newly discovered element, as she believed it to be the most electropositive cation of the elements. Irène Joliot-Curie, one of Perey's supervisors, opposed the name due to its connotation of cat rather than cation; furthermore, the symbol coincided with that which had since been assigned to curium. Perey then suggested francium, after France.
== Procedure == After fasting overnight, a catheter is passed into the patient's duodenum. The patient receives sequential intravenous injections of first secretin then either CKK or a synthetic 8-residue peptide representing the C-terminal 8 of CKK (ceruletide). Duodenal fluid is collected at 15 minute intervals for at least an hour, and the properties of the fluid are used to assess exocrine function of the pancreas. The CCK test may be administered in conjunction with an ultrasound test to visually monitor gall bladder contraction. While the test is usually administered in a supine position, Dr. William Smedley of Wilkes Barre, Pennsylvania has detected previously missed gallbladder abnormalities by administering the test in an erect position. The concentration and output of bicarbonate with the secretin-CCK test is similar to what has been observed with the standard secretin test. The secretin-induced rapid flow of water results in lower and often unreliable enzyme concentrations. CCK also induces gallbladder contraction and the release of bile, which may further dilute enzyme concentrations. As a result, the quantification of total enzyme output (units/min) must be determined through continuous collection of duodenal fluid with or without the use of perfusion markers. Measurement of more than one enzyme (i.e. amylase, lipase, and tryptase) and bicarbonate may improve sensitivity since some patients may possess deficiencies of one parameter and not the others.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.